Related Experiment Videos
Cyclin-dependent kinase inhibitors: cancer killers to neuronal guardians
1Department of Pharmacology, SUNY Upstate Medical University, Syracuse, NY 13210, USA.
Abstract:
The development of small molecule kinase inhibitors as potential cancer therapeutics is an area of intense interest, and a subset of these agents target cyclin-dependent kinase (CDK) activity. Ten distinct CDKs (1-9, 11), when paired with their cyclin activators, are integral to such diverse processes as cell cycle control, neuronal development, and transcriptional regulation. Mutation and/or aberrant expression of certain CDKs and their regulatory counterparts are associated with uncontrolled proliferation and tumorigenesis. As such, CDK selective inhibitors (CDKIs) that attenuate or prevent tumor growth have been developed. Recently, interest in the therapeutic potential of CDKIs has expanded to include neurodegenerative diseases, where dysregulated CDK activity has been linked to the pathogenesis of Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS), and stroke. Specifically, aberrant activation of cell cycle CDKs or CDK5 is associated with apoptosis and neuronal dysfunction in response to various neuronal stressors. To date, CDKIs have shown promise as neuroprotective agents in the research laboratory and, in the future, may prove useful in the neurology clinic.
Insights
Cyclin-dependent kinase inhibitors (CDKIs) show promise in treating cancer by halting tumor growth. Emerging research suggests CDKIs also offer neuroprotection, potentially treating neurodegenerative diseases like Alzheimer's disease.
Area of Science:
- Biochemistry
- Molecular Biology
- Neuroscience
Background:
- Small molecule kinase inhibitors targeting cyclin-dependent kinases (CDKs) are crucial cancer therapeutics.
- CDKs regulate vital cellular processes including cell cycle control and neuronal development.
- Aberrant CDK activity is implicated in tumorigenesis and neurodegenerative diseases such as Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS), and stroke.
Purpose of the Study:
- To explore the therapeutic potential of cyclin-dependent kinase inhibitors (CDKIs).
- To investigate the role of CDKIs in both oncology and neurodegenerative disease treatment.
- To highlight the neuroprotective capabilities of CDKIs in preclinical research.
Main Methods:
- Review of existing literature on CDKIs in cancer and neurodegenerative disease research.
- Analysis of the mechanisms by which CDK dysregulation contributes to disease pathogenesis.
- Examination of preclinical data supporting the neuroprotective effects of CDKIs.
Main Results:
- CDKIs effectively inhibit tumor growth by targeting aberrant CDK activity.
- Dysregulated CDK activity, particularly of cell cycle CDKs and CDK5, is linked to neuronal apoptosis and dysfunction.
- CDKIs demonstrate significant neuroprotective potential in laboratory settings.
Conclusions:
- CDKIs represent a promising therapeutic strategy for various cancers.
- The neuroprotective properties of CDKIs suggest potential applications in treating neurodegenerative disorders.
- Further clinical research may establish CDKIs as valuable agents in neurology.